SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY FROM INSULIN GLARGINE TO INSULIN DETEMIR IN PEOPLE WITH TYPE 2 DIABETES

被引：0

作者：

Malek, R. ^{[1
]}

Galvez, G. G. ^{[2
]}

Hammerby, E. ^{[3
]}

Nikolajsen, A. ^{[3
]}

Henriksen, O. ^{[4
]}

Andersen, M. F. B. ^{[4
]}

机构：

[1] CHU Setif, Setif, Algeria

[2] Inst Jalisciense Invest Diabet & Obesidad, Guadalajara, Jalisco, Mexico

[3] Novo Nordisk AS, Soborg, Denmark

[4] Last Mile PS, Copenhagen K, Denmark

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.2061

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A690 / A690

页数：1

共 50 条

[41] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
Xu, J.
Lan, K.
Wang, J.
[J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
[42] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes
Cheng, Huafeng
Wan, Xu
Ma, Jing
Wu, Bin
[J]. CLINICAL THERAPEUTICS, 2019, 41 (03) : 445 - 455
[43] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
Liu, C.
Tao, L. B.
Wang, F.
[J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
[44] Intensified insulin therapy of type 2 diabetes mellitus: Insulin glargine vs. insulin detemir as basal insulin
Jungmann, Eckart
[J]. DIABETES, 2006, 55 : A118 - A118
[45] SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
Ramirez de Arellano, A.
Morales, C.
De Luis, D.
Ferrario, M. G.
Lizan, L.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
[46] Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting
Valentine, WJ
Palmer, AJ
Lammert, M
Nicklasson, L
Foos, V
Roze, S
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) : 2063 - 2071
[47] Long-term glycaemic control with insulin glargine in Type 2 diabetes
Kacerovsky-Bielesz, G
Dressler, A
Freunscht, R
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 71 (02) : 184 - 191
[48] COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL SUPPORTED ORAL THERAPY (BOT) IN GERMANY
Neilson, A.
Pscherer, S.
Dippel, F. W.
Dietrich, E. S.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A408 - A408
[49] Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients With Type 2 Diabetes Mellitus
Brown, Stephen T.
Grima, Daniel Grima
Sauriol, Luc
[J]. CLINICAL THERAPEUTICS, 2014, 36 (11) : 1576 - 1587
[50] Real World Outcomes of Switching from Insulin Glargine (GLA) to Insulin Detemir (DET) in Medicaid Patients With Type 2 Diabetes
Cao, Zhun
Wei, Wenhui
Miao, Raymond
Thomson, Erin
[J]. DIABETES, 2013, 62 : A648 - A648

← 1 2 3 4 5 →